Under the agreement, PCT, using Sistemic’s patented miRNA profiling system and proprietary analytical approaches, will study the broad applicability of SistemQC technology in stem cell characterization to produce miRNA panels, termed as Key miRNAs or KmiRs, which PCT may look to employ in process optimization and cell characterization in future.
Sistemic chairman and CEO Jim Reid said PCT is a contract development and manufacturing organization (CDMOs) that can count a client with an FDA approved cell therapy (CT) product.
"It is a great achievement for Sistemic to start working with such a progressive and sector-leading company. We aim to assist PCT in developing a more precise understanding of CT products and thereby help the industry to more rapidly bring effective CT products to market," Reid added.
"The CT industry has incredible promise and could be transformational in terms of how we treat a number of diseases that have a huge impact on individuals and healthcare systems alike. In working with PCT we see a clear opportunity to make a significant impact in this vital therapeutic sector."